NEW YORK, Jan 16 – Bayer said Tuesday it had agreed to make an $85 million equity investment in CuraGen as well as provide an additional $39 million in funding in exchange for Curagen’s commitment to use its functional genomics tools to evaluate the pharmaceutical giant’s early-stage pipeline of compounds.

The collaboration is an expandable, five-year deal.

In addition, the companies also announced plans to work together to discover and commercialize small molecule drugs for treating obesity and adult onset diabetes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.